Home » Impax Receives Tentative FDA Approval for Generic Cymbalta
Impax Receives Tentative FDA Approval for Generic Cymbalta
Impax Laboratories confirmed that the U.S. Food and Drug Administration has granted tentative approval of the company’s Abbreviated New Drug Application for generic version of Cymbalta delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules.
TheStreet
TheStreet
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May